Angle Plc has raised a further £2.8 million to complement a £12.2 million fundraising announced on 5 October. The monies will help the company finance the purchase of assets from Canada-based Axela Inc that will broaden its liquid biopsy capabilities enabling it to both harvest circulating tumour cells from patients and analyse them for gene expression.
